Trial · NCT02402036
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
NCT02402036, Phase 2, Terminated, Georgetown University; results first posted 2019-01-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer. Trials, record NCT02402036. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02402036
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
- NCT number
- NCT02402036
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Georgetown University
- Conditions
- Colon Cancer
- Interventions
- Regorafenib
- First posted
- 2015-03-30
- Last updated
- 2019-01-29
- Results first posted
- 2019-01-29
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum microRNA Quantification | 2 years | Serum microRNAs will be quantified using miScript MiRNA PCR arrays |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Serum microRNA Quantification | 2 years | Due to issues with recruitment and the principal investigator leaving the institution, no analysis of the collected samples was performed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Regorafenib | 10 | |
| Overall Study | COMPLETED | Regorafenib | 10 | |
| Overall Study | NOT COMPLETED | Regorafenib | 0 |
Source ClinicalTrials.gov
Adverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | General disorders | Regorafenib | 5 | 10 | 7 |
| other | Alkaline phosphatase increased | General disorders | Regorafenib | 3 | 10 | 3 |
| other | Anemia | Blood and lymphatic system disorders | Regorafenib | 2 | 10 | 3 |
| other | Aspartate aminotransferase increased | Hepatobiliary disorders | Regorafenib | 3 | 10 | 5 |
| other | Colonic obstruction | Gastrointestinal disorders | Regorafenib | 1 | 10 | 1 |
| other | Creatinine increased | Renal and urinary disorders | Regorafenib | 1 | 10 | 1 |
| other | Elevated total bilirrubin | Hepatobiliary disorders | Regorafenib | 2 | 10 | 3 |
| other | High Neutrophils | Immune system disorders | Regorafenib | 1 | 10 | 1 |
| other | Hypoalbuminemia | Hepatobiliary disorders | Regorafenib | 4 | 10 | 7 |
| other | Hyponatremia | General disorders | Regorafenib | 2 | 10 | 3 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Regorafenib | 1 | 10 |
| Total, other adverse events | Regorafenib | 10 | 10 |
| Total, serious adverse events | Regorafenib | 5 | 10 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28712102 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02402036
GET https://conductscience.org/api/trials/v1/NCT02402036/events?page=2